Humana Inc. (NYSE:HUM) Stake Lifted by Truist Financial Corp

Truist Financial Corp raised its holdings in shares of Humana Inc. (NYSE:HUM) by 15.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,865 shares of the insurance provider’s stock after purchasing an additional 1,199 shares during the quarter. Truist Financial Corp’s holdings in Humana were worth $2,249,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in HUM. Creative Financial Designs Inc. ADV boosted its holdings in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP boosted its holdings in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. Atwood & Palmer Inc. boosted its holdings in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Finally, LRI Investments LLC boosted its holdings in Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.32% of the stock is currently owned by company insiders.

Humana Stock Performance

Shares of HUM opened at $255.06 on Thursday. The company’s fifty day moving average is $270.12 and its 200-day moving average is $288.06. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The firm has a market cap of $30.77 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.39%. Humana’s payout ratio is presently 35.58%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HUM. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Barclays upped their price target on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Wells Fargo & Company reduced their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Nineteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.